Shire to Resubmit Dry-Eye Disease Drug to FDA With New Study DataShire to Resubmit Dry-Eye Disease Drug to FDA With New Study Data

Shire said its dry-eye disease drug lifitegrast significantly improved patient symptoms in a new study, supporting a re-submission of the medicine to U.S. regulators early next year. Reuters Health Information

Source: Medscape Ophthalmology Headlines - October 28, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news